Mediators of Inflammation

Mediators of Inflammation / 2019 / Article

Research Article | Open Access

Volume 2019 |Article ID 6175091 | 14 pages |

Isorhamnetin Inhibits Liver Fibrosis by Reducing Autophagy and Inhibiting Extracellular Matrix Formation via the TGF-β1/Smad3 and TGF-β1/p38 MAPK Pathways

Academic Editor: Vera L. Petricevich
Received06 Mar 2019
Revised25 May 2019
Accepted16 Jun 2019
Published31 Jul 2019


Objective. Liver fibrosis is a consequence of wound-healing responses to chronic liver insult and may progress to liver cirrhosis if not controlled. This study investigated the protection against liver fibrosis by isorhamnetin. Methods. Mouse models of hepatic fibrosis were established by intraperitoneal injection of carbon tetrachloride (CCl4) or bile duct ligation (BDL). Isorhamnetin 10 or 30 mg/kg was administered by gavage 5 days per week for 8 weeks in the CCl4 model and for 2 weeks in the BDL model. Protein and mRNA expressions were assayed by western blotting, immunohistochemistry, and quantitative real-time polymerase chain reaction. Results. Isorhamnetin significantly inhibited liver fibrosis in both models, inhibiting hepatic stellate cell (HSC) activation, extracellular matrix (ECM) deposition, and autophagy. The effects were associated with downregulation of transforming growth factor β1 (TGF-β1) mediation of Smad3 and p38 mitogen-activated protein kinase (MAPK) signaling pathways. Conclusion. Isorhamnetin protected against liver fibrosis by reducing ECM formation and autophagy via inhibition of TGF-β1-mediated Smad3 and p38 MAPK signaling pathways.

1. Introduction

Liver fibrosis is associated with long-term chronic liver diseases caused by viral infection, metabolic disorders, drugs, cholestatic diseases, alcohol abuse, or immune attack [1]. Sustained liver insult leads to progressive fibrosis and ultimately to cirrhosis and hepatocellular carcinoma. Liver fibrosis represents a significant global health burden [2]. Antiviral drugs or immunosuppressive agents may prevent or attenuate liver fibrosis in a subset of cases. However, effective treatments are not available for many patients, leading to end-stage liver cirrhosis and poor prognosis [3, 4]. The lack of preventive and therapeutic interventions has created an urgent need for effective antifibrotic agents.

Liver fibrosis is characterized by overproduction of collagen type I (Col-1) and deposition of extracellular matrix (ECM) in the subendothelial space [5, 6]. Hepatic stellate cells (HSCs) are the main source of ECM. They are quiescent under physiological conditions and store hepatic retinoid and vitamin A [7]. Activation of HSCs by autocrine or paracrine stimuli promotes development of a myofibroblast-like phenotype, with loss of lipid droplets, and expression α-smooth muscle actin (α-SMA) [8]. Activated HSCs are responsive to both fibrogenic and proliferative stimuli that promote the proliferation of fibrogenic cells and the production of ECM. The activity of matrix metalloproteinase (MMP) and tissue inhibitor of matrix metalloproteinase (TIMP) enzymes, which regulate ECM formation and removal, is also disturbed in liver fibrosis [9]. The complex changes during liver fibrosis result in distortion and disruption of hepatic tissue structure and function [10]. Inhibition of HSC activation and proliferation and maintaining balanced ECM production and degradation are key potential liver fibrosis treatment targets.

Transforming growth factor β (TGF-β) is present in normal liver tissue, but increased expression occurs at all stages of progressive liver disease, including fibrosis [11]. Production of TGF-β1 contributes to HSC activation and excessive accumulation of ECM, thereby promoting liver fibrosis [12]. Current evidence suggests that regulating the TGF-β1 pathway may attenuate fibrogenesis [11, 1316].

Autophagy helps to maintain normal liver homeostasis by removal of defective organelles and components. Autophagy initiates with the formation of autophagosomes, which are vacuoles bounded by a double membrane that fuses with lysosomes and delivers the defective components, which are then digested [17]. It is well-known that autophagy is increased with HSC activation in mouse fibrosis models and in human fibrotic liver tissue. Blocking autophagy in HSCs inhibits HSC activation and alleviates liver fibrosis [18, 19]. Thus, interventions involving autophagy in HSCs may be an attractive therapeutic target for hepatic fibrosis.

Isorhamnetin (IH) is a flavonol aglycone isolated from the plant Hippophae rhamnoides L. that has anti-inflammatory, antioxidant, and antitumor activity [20, 21]. IH has hepatoprotective effects by inhibiting hepatocyte autophagy and apoptosis [20]. Zheng et al. reported that IH protected against pulmonary fibrosis induced by bleomycin in mouse models by inhibiting epithelial-mesenchymal transition and endoplasmic reticulum stress [22]. Recently, Yang et al. reported that IH attenuated carbon tetrachloride- (CCl4-) induced liver fibrosis by downregulating TGF-β/Smad signaling and reducing oxidative stress [23]. However, whether IH could attenuate bile duct ligation- (BDL-) induced hepatic fibrosis is unclear, and the involvement of autophagy has not been investigated.

Based on these, this study is aimed at investigating the role of IH on CCl4- or BDL-induced mouse models of hepatic fibrosis, mainly focus on the involvement of the TGF-β1/Smad3 and TGF-β1/p38 MAPK pathway signaling and autophagy.

2. Materials and Methods

2.1. Reagents

IH was purchased from Sigma-Aldrich (St. Louis, MO, USA), and CCl4 was purchased from Sinopharm (Shanghai, China). Primers used in real-time quantitative polymerase chain reaction (qPCR) assays were from Generay (Shanghai, China). α-SMA (cat. no. 14395-1-AP), Col-1 (cat. no. 14695-1-AP), MMP-2 (cat. no. 10373-2-AP), TIMP1 (cat. no. 10753-1-AP), p38 (cat. no. 14064-1-AP), peroxisome proliferator-activated receptor γ (PPAR-γ; cat. no. 16643-1-AP), TGF-β1 (cat. no. 21898-1-AP), beclin-1 (cat. no. 11306-1-AP), and LC3 (cat. no. 14600-1-AP) antibodies were from Proteintech (Chicago, IL, USA). Phospho-p38 (p-p38; cat. no. 4511) was from Cell Signaling Technology (Danvers, MA, USA). F4/80 (cat. no. GB11027) antibody was from Servicebio (Wuhan, China). Phospho-Smad3 (p-Smad3; cat. no. ab52903) and Smad3 (cat. no. ab40854) antibodies were obtained from Abcam (Cambridge, MA, USA). Goat anti-mouse (cat. no. 926-68020) and anti-rabbit (cat. no. 926-32211) secondary antibodies were from LI-COR Biosciences (Lincoln, NE, USA).

2.2. Animals

Male C57 mice (22–24 g, 8 weeks old) were obtained from Shanghai Laboratory Animal Co. Ltd. (Shanghai, China) and housed under constant conditions (, and a 12 h/12 h light/dark cycle) with a standard diet. The study was approved by the Animal Care and Use Committee of Shanghai Tongji University (Approval no. SHDSYY-2018-1474) and conducted following the National Institutes of Health Guidelines.

2.2.1. Animal Experiment

A preliminary experiment was performed before the formal experiment to show the safety of IH treatment and sham operation on the liver. Mice were randomly allocated in four groups (5 animals per group): a control group that accepted no treatment, a vehicle group that was injected intraperitoneally with olive oil three times a week, a sham operation group with laparotomy only, or an IH group gavaged with 30 mg/kg IH in saline five times a week. The mice were treated for 8 weeks and sacrificed under anesthesia. Serum and hepatic tissues were obtained for biochemical assays and histopathology.

We then established the following two animal models to study the effects of IH on liver fibrosis.

Mice in the CCl4-induced fibrosis model were given with 10% CCl4 (1 mL/kg, diluted in olive oil; i.p.) three times a week for 8 weeks. IH in saline was given by gavage at either 10 or 30 mg/kg five days per week for 8 weeks. Mice were randomly allocated in four groups (8 animals per group): a vehicle control group injected intraperitoneally with olive oil, a model group intraperitoneal injection with CCl4, intraperitoneal injection of CCl4 and 10 mg/kg IH, or intraperitoneal injection of CCl4 and 30 mg/kg IH.

Mice in the BDL model were randomly allocated in four groups (eight animals each group): a sham control group, BDL group, BDL+10 mg/kg IH group, and BDL+30 mg/kg IH group. Surgery was performed as previously described [14]. IH was administrated 24 h after the surgery. Mice were given 10 or 30 mg/kg IH by gavage for 5 days per week for 2 weeks.

2.3. Biochemical Detections

Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were assayed with microplate detection kits (Jiancheng Bioengineering Institute, Nanjing, China) and read by spectrophotometry using an AU1000 automated chemistry analyzer (Olympus Corporation, Tokyo, Japan). Liver hydroxyproline was determined with detection kits (Biocheck, Foster City, CA, USA) according to the manufacturer’s protocol. Serum TGF-β1 was measured using enzyme-linked immunosorbent assay (ELISA) kits (mlbio, China).

2.4. Histopathology

Fresh liver tissues were fixed with 4% paraformaldehyde for 2 days at room temperature, embedded in paraffin, and then sectioned at 5 μm. The thin sections were stained with hematoxylin and eosin (H&E) or Masson’s trichrome following standard methods [13]. The tissues were viewed under light microscopy to evaluate liver injury and extent of collagen fibers.

2.5. qPCR

Total RNA was isolated from frozen mouse hepatic tissues with TRIzol reagent (Tiangen Biotech, Beijing, China) according to the standard protocol. Then, 0.5 μg extracted RNA was converted to cDNA through TaKaRa reverse transcription kits (Biotechnology, Dalian, China). mRNA expression was assayed with SYBR Premix EX Taq (TaKaRa Biotechnology), using a 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). The sequences of primers are listed in Table 1.

GeneAmplicon sizePrimer sequencePosition


2.6. Western Blotting

Total protein was extracted from frozen tissues and quantified by standard procedures. Proteins (80 μg) were isolated by sodium dodecylsulfate-polyacrylamide gel electrophoresis, and transferred onto polyvinylidene fluoride membranes. Then, blots were blocked with 5% defatted milk powder and sequentially incubated with primary antibodies and secondary goat anti-mouse or anti-rabbit antibodies [15]. The primary antibodies and dilutions were beclin-1 (1 : 1000), LC3 (1 : 500), α-SMA (1 : 1000), PPAR-γ (1 : 500), Col-1 (1 : 500), MMP-2 (1 : 1000), TIMP1 (1 : 1000), TGF-β1 (1 : 500), p38 (1 : 1000), p-p38 (1 : 1000), Smad3 (1 : 500), p-Smad3 (1 : 500), and β-actin (1 : 1000). The secondary antibodies were at dilution of 1 : 2000. The blots were read with an Odyssey two-color infrared laser imaging system (LI-COR Biosciences).

2.7. Immunohistochemistry

The prepared paraffin-embedded sections were dewaxed, dehydrated, and incubated in 3% hydrogen peroxide. Antigen retrieval was performed by four cycles of heating to 100°C and cooling citrate buffer. Nonspecific protein binding sites were blocked with 5% bovine serum albumin. The sections were incubated with α-SMA, Col-1, beclin-1, TGF-β1, p-p38, p-Smad3, PPAR-γ, and F4/80 primary antibodies at 1 : 500 dilutions at 4°C overnight. After incubating with secondary antibody (1 : 200 dilution), antibody binding was visualized with a diaminobenzidine kit. Positive areas were observed by light microscopy.

2.8. Statistical Analysis

Statistical differences were evaluated using analysis of variance followed by Tukey’s correction for multiple comparisons. Data were analyzed with SPSS version 20.0 (Chicago, IL, USA). A value of was considered statistically significant.

3. Results

3.1. IH and Sham Operation Had No Harmful Effects on the Liver

Serum ALT and AST and liver hydroxyproline in normal controls, sham-operated, vehicle-treated, and IH-treated mice were not significantly different (Figure 1(a)). H&E and Masson staining did not find any obvious pathological changes in the four groups (Figure 1(b)). The results indicated that IH, vehicle, and sham operation had no harmful effects on the liver.

3.2. IH Attenuated Liver Fibrosis Induced by CCl4 and BDL in Mouse

ALT and AST, two markers of liver injury, increased significantly following CCl4 injection and BDL surgery (Figure 2(a)). IH decreased liver enzymes in a dose-dependent manner, which indicated that IH protected the liver from chronic injury. Hydroxyproline, a constituent of liver collagen, also increased significantly in CCl4- and BDL-treated mice. As shown in Figure 2(a), IH dose-dependently decreased liver hydroxyproline levels. Histological evaluation (Figure 2(b)) was performed by H&E and Masson staining. H&E-stained tissue revealed that inflammatory infiltration, hepatocyte swelling and necrosis, damage of the liver lobules, and the formation of fibrous septa were prominent in both CCl4- and BDL-treated mice. Bile duct proliferation was also evident in mice with BDL-induced liver fibrosis. The histological changes observed in both fibrosis models were significantly attenuated by IH. The extent of the improvement increased with the IH dose. Masson staining demonstrated extensive collagen deposition in both fibrosis models. Collagen deposition was significantly reduced by IH. The results confirmed the protective effects of IH against liver fibrosis in both mouse models.

3.3. IH Inhibited Massive Macrophage Recruitment in the Liver

F4/80 is a marker of the liver macrophages (Kupffer cells). We determined the expression of F4/80 to analyze the effect of IH treatment on macrophage infiltration. The mRNA expression of F4/80 was significantly elevated in the fibrotic livers induced by CCl4 and BDL when compared to the normal livers determined by qPCR; however, IH markedly reduced the expression of F4/80 in liver tissues (Figure 3(a)). Immunohistochemistry of F4/80 showed that spindle-shaped F4/80-positive cells increased significantly in the hepatic fibrosis groups compared with the control groups. However, the elevation was obviously inhibited by IH treatment (Figure 3(b)). The results indicated that IH could inhibit chronic CCl4- and cholestasis-induced massive macrophage recruitment in liver tissues.

3.4. IH Inhibited HSC Activation and ECM Formation

α-SMA and PPAR-γ are considered as markers of HSC activation and quiescence, respectively [2426]. mRNA and protein levels of α-SMA were significantly upregulated, whereas the PPAR-γ expression was markedly downregulated in mice exposed to chronic CCl4 and BDL compared with controls. IH dose-dependently reduced the α-SMA expression and increased the PPAR-γ expression in liver tissues. Collagen (especially types I and III) is the main component of ECM in liver tissues. The qPCR, western blotting, and immunohistochemistry results showed that the Col-1 expression in the liver was obviously elevated in both fibrosis model mice compared with controls, whereas IH significantly reduced the collagen expression in liver tissues (Figures 4(a)4(c)). MMP-2 has been shown to be involved in suppressing the collagen expression, and TIMP1 overexpression has been associated with inhibiting ECM clearance [27, 28]. As shown in Figures 4(a) and 4(b), the MMP-2 expression was significantly decreased, while the expression of TIMP1, an MMP inhibitor, was increased in both fibrosis models. As shown by qPCR and western blotting, both mRNA and protein expressions were affected in the fibrosis models. The results are consistent with the activation of HSC and overproduction and impaired degradation of ECM in the fibrosis models. IH decreased the expression of TIMP1 and increased the MMP-2 expression at both mRNA and protein levels in a dose-dependent manner (Figures 4(a)4(c)). The results showed that IH inhibited HSC activation and maintained the balance of ECM production and degradation in both fibrosis models.

3.5. IH Reduced Autophagy in Both Liver Fibrosis Models

Beclin-1 and LC3 expressions are associated with autophagosome formation and considered autophagy markers. mRNA and protein levels of beclin-1 and LC3 were significantly elevated in both fibrosis models compared with control mice (Figures 5(a) and 5(b)); however, IH prevented their increase in a dose-dependent way. The results of beclin-1 immunohistochemical staining were consistent with the results of western blotting (Figure 5(c)). The results indicated that IH inhibited autophagy in both liver fibrosis mouse models.

3.6. IH Downregulated TGF-β1-Activated Smad3 and p38 MAPK Signaling Pathways

The expression of TGF-β1, the most potent fibrogenic cytokine in the liver, was prominently increased in both fibrosis models, but IH treatment significantly decreased both mRNA and protein levels of TGF-β1 in liver tissues (Figures 6(b)6(d)). The changes of TGF-β1 in serum were consistent with those in liver tissues (Figure 6(a)). We then focused on p-Smad3 and p-p38 MAPK, which are the downstream signaling molecules of TGF-β1. As shown by western blot assays and immunohistochemistry (Figures 6(c) and 6(d)), the expression of p-Smad3 and p-p38 MAPK proteins was upregulated in liver fibrosis tissues compared with controls, while both were dose-dependently attenuated by IH. The results demonstrated that IH improved liver fibrosis through downregulating TGF-β1 mediation of Smad3 and p38 MAPK signaling.

4. Discussion

Hepatic fibrosis, or liver scarring, is a response to liver injury. Sustained insult may lead to progression of liver fibrosis that produces serious, irreversible liver disease, cirrhosis, and hepatic carcinoma [1, 5, 6]. Therapeutic strategies for liver fibrosis are still limited. Studies showed that blocking the TGF-β1 pathway could be a potential strategy for liver fibrosis [1316]. TβR antagonists could effectively inhibit the TGF-β pathway and showed the antifibrotic potency both in vitro and in vivo [29, 30]. However, the on-target toxicity of TβR antagonists, especially cardiac injuries, should be highly concerned. The concentration must be carefully controlled to reduce the toxicity, which limited the development and application of TβR antagonists [3133]. Therefore, discovering an effective and safe therapeutic agent for liver fibrosis is urgently needed. Our previous study showed that IH treatment is hepatoprotective [20]. Recent studies also showed the protective role of IH in cardiovascular diseases [34], lung injury [35], and renal damage [36]. These studies demonstrated that IH treatment is safe and protective for multiple organ function in animal models. Remarkably, IH has previously been reported to show antifibrosis activity in lung and cardiac muscle [22, 37]. IH was also found to reduce the extent of CCl4-induced hepatic fibrosis by reducing oxidative stress [23]. Therefore, IH might be a promising candidate for hepatic fibrosis treatment.

In this study, we investigated the antifibrotic effects of IH in both CCl4- and BDL-induced mouse models of liver fibrosis. Intraperitoneal injection of CCl4 is a reliable method for the establishment of stable fibrotic models. The pathological appearance is similar to that of human hepatic fibrosis caused by hepatitis B infection [38]. BDL-induced fibrosis is similar to injury caused by cholestatic obstruction [39]. Our results showed that IH at both 10 and 30 mg/kg effectively protected hepatic function and improved liver pathology changes in both fibrosis models. The therapeutic mechanism of IH in liver fibrosis involves downregulating the TGF-β1/Smad3 and TGF-β1/p38 MAPK pathways. Therefore, the present study indicated that IH could be an attractive agent for the clinical therapy of liver fibrosis.

ALT and AST are two liver enzymes that reflect hepatocyte integrity. Liver enzymes leak into the bloodstream by liver injury and increase their levels in serum, which reflects hepatocyte injury [40]. The elevated ALT and AST levels were recovered following IH treatment in both fibrotic models, which suggested that IH protected hepatocytes from chronic injury. In parallel, IH treatment alleviated inflammation infiltration in liver sections. Our previous study also showed that IH inhibited hepatocyte apoptosis and autophagy induced by inflammation, thereby improving liver function [20]. It indicated that the hepatoprotective role of IH could be attributed to the anti-inflammation effect [41, 42].

The importance of HSC activation in hepatic fibrosis is well known. Chronic damage of hepatic tissue leads to activation of resting HSCs and transdifferentiation into myofibroblasts. The myofibroblasts express α-SMA, lose their lipid droplets, and contribute to the formation of ECM [8]. The progressive accumulation of ECM in the Disse space produces mechanical irritation that continues to drive HSC activation [24], and the binding and accumulation of growth factors within the ECM further enhance HSC proliferation [24, 43]. Therefore, decreased matrix deposition may attenuate liver fibrosis. ECM production is modulated by TIMPs and MMPs. MMPs degrade ECM proteins, while TIMPs inhibit the proteolytic activity of MMPs. The balance between MMP and TIMP activity is disturbed in liver fibrosis [28, 44]. Shifting the MMP-TIMP balance facilitates the deposition of ECM. In this study, changes in α-SMA and Col-1 expressions revealed that HSC activation and ECM accumulation were reduced in liver tissues treated with IH. We also examined the expression of PPAR-γ, a quiescent HSC marker, in liver tissues. Studies have shown that PPAR-γ is involved in maintaining the quiescent HSC phenotype and acts as a negative regulator in HSC transdifferentiation [25, 26]. The induction of PPAR-γ by IH reflects the alleviation of liver fibrosis and also plays a great role in maintaining quiescence of HSCs [45, 46]. Additionally, the study confirmed, as would be expected, that the balanced expression of MMP-2 and TIMP1 was changed in both fibrosis models, but it was recovered by IH treatment. The results indicate that IH attenuated liver fibrosis by inhibiting HSC activation and regulating ECM balance.

Immune cells, especially liver macrophages (Kupffer cells), also play a pivotal role in hepatic fibrosis. In response to liver injury, massive Kupffer cells recruit to the liver, and produce inflammatory cytokines (such as TGF-β1), which perpetuate inflammation and mediate HSC activation [47, 48]. Our result indicated that IH could effectively inhibit inflammation and regulate Kupffer cell recruitment in the chronic damaged liver, which contributed to the alleviation of liver fibrosis caused by chronic CCl4 and cholestasis exposure [48].

TGF-β1 is a fibrogenic cytokine secreted by both liver macrophages (Kupffer cells) and activated HSCs [11], and it promotes transdifferentiation and proliferation of HSCs. It targets the α1 and α2 procollagen type I genes and TIMP-1 and TIMP-2 expressions [11, 4952]. The TGF-β1 expression mediates intracellular signaling through the Smad and p38 MAPK pathways [53]. Binding of TGF-β to the TGF-β receptor (TβR) type II transphosphorylates TβR type I, which subsequently phosphorylates downstream pathways of Smad [11, 54]. The phosphorylated Smad protein then combines with Smad4, and the complex translocates into the nucleus where it regulates the transcription of genes coding collagens, α-SMA, and TIMP1 [12, 55, 56]. Suppression of Smad3 in HSCs is known to inhibit the Col-1 expression and reduce liver fibrosis [12, 57, 58]. In addition, other signal transducers such as the p38 MAPK pathway can also be medicated by activation of TβR. Previous studies have found that p38 MAPK signaling independently, and additively along with Smad, regulates collagen transcription [5961]. p38 MAPK signaling also increases the stability of the Col-1 mRNA expression [61]. The evidence supports fibrogenic activity by Smad3 and p38 MAPK in TGF-β1-induced hepatic fibrosis. In this study, we explored the effect of IH on TGF-β1/Smad3 and TGF-β1/p38 MAPK pathways. The results found that IH blocked the increase of the TGF-β1 expression during liver injury. Accordingly, the downstream molecules, p-Smad3 and p-p38, were downregulated with IH treatment. Therefore, IH treatment efficiently blocked the TGF-β1 pathway, which was involved in the antifibrosis activity of IH.

Autophagy maintains liver homeostasis by degrading and recycling aggregated proteins and damaged organelles [17], but inappropriate activation of autophagy has been associated with various diseases, including liver fibrosis [17, 62]. Autophagy provides energy through digestion of intracellular lipids to support HSC activation and promote fibrosis [18, 63]. Knockout of the autophagy-related Atg5 gene, or treatment with the autophagy inhibitor 3-methyladenine, reduces HSC activation [19, 64]. Treating HSCs with 3-methyladenine also inhibits HSC proliferation [62]. Autophagy thus appears to be required for both HSC activation and proliferation and may be a novel target for the therapy of liver fibrosis. Our previous work also shows that inhibiting autophagy plays an important role in attenuating liver fibrosis [1316]. Lu et al. reported that IH protected the liver against acute concanavalin A-induced injury by inhibiting autophagy [20]. In our study, we found that IH inhibited autophagy in both liver fibrosis models. It is reported that TGF-β1 can upregulate autophagy [65] and inhibiting TGF-β1/Smad3 signaling can suppress autophagy [13, 66]. Inhibition of the TGF-β1/Smad3 pathway by IH was confirmed in this study. Therefore, we concluded that IH reduced autophagy and alleviated liver fibrosis by downregulating the TGF-β1/Smad3 signaling pathway.

In summary, IH alleviated liver fibrosis induced by CCl4 and BDL in mice (Figure 7). It inhibited the production of TGF-β1 secreted by Kupffer cells and activated HSCs. A lack of TGF-β1 downregulated downstream signaling by the Smad3 and p38 MAPK signaling pathways, contributing to the inhibition of HSC activation and ECM production. Autophagy was inhibited by downregulation of the TGF-β1/Smad3 signaling pathway, and the resulting energy deficit decreased HSC activation.

The study demonstrates the potential protective role of IH against both noncholestatic and cholestatic fibrosis. This is the first study to show that inhibiting autophagy in HSCs is involved in the antifibrotic mechanism of IH. It also highlights the key role of regulating autophagy and TGF-β1 pathways in the treatment of hepatic fibrosis. However, other mechanisms of action and the safety of IH for clinical applications remain to be investigated.

5. Conclusions

The study confirmed the protective effects of IH against liver fibrosis in mice. The mechanism of the antifibrotic effects of IH involves inhibition of TGF-β1-mediated Smad3 and p38 MAPK signaling pathways, thereby reducing autophagy and ECM formation.

Data Availability

The data used to support the findings of the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Ning Liu and Jiao Feng contributed equally to this work and shared first authorship.


This study was supported by Shanghai Tenth Hospital’s improvement plan for National Natural Science Foundation of China (No. SYGZRPY2017003) and Shanghai Natural Science Foundation (No. 19ZR1439900).


  1. M. M. Aydin and K. C. Akcali, “Liver fibrosis,” The Turkish Journal of Gastroenterology, vol. 29, no. 1, pp. 14–21, 2018. View at: Publisher Site | Google Scholar
  2. A. A. Mokdad, A. D. Lopez, S. Shahraz et al., “Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis,” BMC Medicine, vol. 12, no. 1, p. 145, 2014. View at: Publisher Site | Google Scholar
  3. S. Davison, “Assessment of liver disease in cystic fibrosis,” Paediatric Respiratory Reviews, vol. 27, pp. 24–27, 2018. View at: Publisher Site | Google Scholar
  4. A. Altamirano-Barrera, B. Barranco-Fragoso, and N. Mendez-Sanchez, “Management strategies for liver fibrosis,” Annals of Hepatology, vol. 16, no. 1, pp. 48–56, 2017. View at: Publisher Site | Google Scholar
  5. U. E. Lee and S. L. Friedman, “Mechanisms of hepatic fibrogenesis,” Best Practice & Research Clinical Gastroenterology, vol. 25, no. 2, pp. 195–206, 2011. View at: Publisher Site | Google Scholar
  6. S. L. Friedman, “Mechanisms of hepatic fibrogenesis,” Gastroenterology, vol. 134, no. 6, pp. 1655–1669, 2008. View at: Publisher Site | Google Scholar
  7. T. Tsuchida and S. L. Friedman, “Mechanisms of hepatic stellate cell activation,” Nature Reviews Gastroenterology & Hepatology, vol. 14, no. 7, pp. 397–411, 2017. View at: Publisher Site | Google Scholar
  8. S. L. Friedman, “Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver,” Physiological Reviews, vol. 88, no. 1, pp. 125–172, 2008. View at: Publisher Site | Google Scholar
  9. E. Roeb, “Matrix metalloproteinases and liver fibrosis (translational aspects),” Matrix Biology, vol. 68-69, pp. 463–473, 2018. View at: Publisher Site | Google Scholar
  10. M. Baues, A. Dasgupta, J. Ehling et al., “Fibrosis imaging: current concepts and future directions,” Advanced Drug Delivery Reviews, vol. 121, pp. 9–26, 2017. View at: Publisher Site | Google Scholar
  11. S. Dooley and P. ten Dijke, “TGF-β in progression of liver disease,” Cell and Tissue Research, vol. 347, no. 1, pp. 245–256, 2012. View at: Publisher Site | Google Scholar
  12. F. Xu, C. Liu, D. Zhou, and L. Zhang, “TGF-β/SMAD pathway and its regulation in hepatic fibrosis,” The Journal of Histochemistry and Cytochemistry, vol. 64, no. 3, pp. 157–167, 2016. View at: Publisher Site | Google Scholar
  13. J. Feng, K. Chen, Y. Xia et al., “Salidroside ameliorates autophagy and activation of hepatic stellate cells in mice via NF-κB and TGF-β1/Smad3 pathways,” Drug Design, Development and Therapy, vol. 12, pp. 1837–1853, 2018. View at: Publisher Site | Google Scholar
  14. C. Guo, J. Li, K. Chen et al., “Protective effect of fucoidan from Fucus vesiculosus on liver fibrosis via the TGF-β1/Smad pathway-mediated inhibition of extracellular matrix and autophagy,” Drug Design, Development and Therapy, vol. 10, pp. 619–630, 2016. View at: Publisher Site | Google Scholar
  15. T. Liu, L. Xu, C. Wang et al., “Alleviation of hepatic fibrosis and autophagy via inhibition of transforming growth factor-β1/Smads pathway through shikonin,” Journal of Gastroenterology and Hepatology, vol. 34, no. 1, pp. 263–276, 2019. View at: Publisher Site | Google Scholar
  16. L. Wu, Q. Zhang, W. Mo et al., “Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-β1/Smads and PI3K/Akt pathways,” Scientific Reports, vol. 7, no. 1, p. 9289, 2017. View at: Publisher Site | Google Scholar
  17. A. Mallat, J. Lodder, F. Teixeira-Clerc, R. Moreau, P. Codogno, and S. Lotersztajn, “Autophagy: a multifaceted partner in liver fibrosis,” BioMed Research International, vol. 2014, Article ID 869390, 7 pages, 2014. View at: Publisher Site | Google Scholar
  18. L. F. R. Thoen, E. L. M. Guimarães, L. Dollé et al., “A role for autophagy during hepatic stellate cell activation,” Journal of Hepatology, vol. 55, no. 6, pp. 1353–1360, 2011. View at: Publisher Site | Google Scholar
  19. V. Hernández–Gea, Z. Ghiassi–Nejad, R. Rozenfeld et al., “Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues,” Gastroenterology, vol. 142, no. 4, pp. 938–946, 2012. View at: Publisher Site | Google Scholar
  20. X. Lu, T. Liu, K. Chen et al., “Isorhamnetin: a hepatoprotective flavonoid inhibits apoptosis and autophagy via P38/PPAR-α pathway in mice,” Biomedicine & Pharmacotherapy, vol. 103, pp. 800–811, 2018. View at: Publisher Site | Google Scholar
  21. L. Ramachandran, K. A. Manu, M. K. Shanmugam et al., “Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor γ activation pathway in gastric cancer,” The Journal of Biological Chemistry, vol. 287, no. 45, pp. 38028–38040, 2012. View at: Publisher Site | Google Scholar
  22. Q. Zheng, M. Tong, B. Ou, C. Liu, C. Hu, and Y. Yang, “Isorhamnetin protects against bleomycin-induced pulmonary fibrosis by inhibiting endoplasmic reticulum stress and epithelial-mesenchymal transition,” International Journal of Molecular Medicine, vol. 43, no. 1, pp. 117–126, 2019. View at: Publisher Site | Google Scholar
  23. J. H. Yang, S. C. Kim, K. M. Kim et al., “Isorhamnetin attenuates liver fibrosis by inhibiting TGF-β/Smad signaling and relieving oxidative stress,” European Journal of Pharmacology, vol. 783, pp. 92–102, 2016. View at: Publisher Site | Google Scholar
  24. T. Higashi, S. L. Friedman, and Y. Hoshida, “Hepatic stellate cells as key target in liver fibrosis,” Advanced Drug Delivery Reviews, vol. 121, pp. 27–42, 2017. View at: Publisher Site | Google Scholar
  25. S. Hazra, S. Xiong, J. Wang et al., “Peroxisome proliferator-activated receptor γ induces a phenotypic switch from activated to quiescent hepatic stellate cells,” The Journal of Biological Chemistry, vol. 279, no. 12, pp. 11392–11401, 2004. View at: Publisher Site | Google Scholar
  26. A. Yoneda, K. Sakai-Sawada, Y. Niitsu, and Y. Tamura, “Vitamin A and insulin are required for the maintenance of hepatic stellate cell quiescence,” Experimental Cell Research, vol. 341, no. 1, pp. 8–17, 2016. View at: Publisher Site | Google Scholar
  27. B. D. Radbill, R. Gupta, M. C. M. Ramirez et al., “Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression,” Digestive Diseases and Sciences, vol. 56, no. 2, pp. 406–416, 2011. View at: Publisher Site | Google Scholar
  28. H. Yoshiji, S. Kuriyama, Y. Miyamoto et al., “Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model,” Hepatology, vol. 32, no. 6, pp. 1248–1254, 2000. View at: Publisher Site | Google Scholar
  29. T. Luangmonkong, S. Suriguga, E. Bigaeva et al., “Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis,” British Journal of Pharmacology, vol. 174, no. 18, pp. 3107–3117, 2017. View at: Publisher Site | Google Scholar
  30. J. H. Park, S. H. Ryu, E. K. Choi et al., “SKI2162, an inhibitor of the TGF-β type I receptor (ALK5), inhibits radiation-induced fibrosis in mice,” Oncotarget, vol. 6, no. 6, pp. 4171–4179, 2015. View at: Publisher Site | Google Scholar
  31. L. C. Spender, G. J. Ferguson, G. D. Hughes et al., “Preclinical evaluation of AZ12601011 and AZ12799734, inhibitors of transforming growth factor β superfamily type 1 receptors,” Molecular Pharmacology, vol. 95, no. 2, pp. 222–234, 2019. View at: Publisher Site | Google Scholar
  32. A. de Gramont, S. Faivre, and E. Raymond, “Novel TGF-β inhibitors ready for prime time in onco-immunology,” OncoImmunology, vol. 6, no. 1, article e1257453, 2017. View at: Publisher Site | Google Scholar
  33. M. J. Anderton, H. R. Mellor, A. Bell et al., “Induction of heart valve lesions by small-molecule ALK5 inhibitors,” Toxicologic Pathology, vol. 39, no. 6, pp. 916–924, 2011. View at: Publisher Site | Google Scholar
  34. J. Sun, G. Sun, X. Meng et al., “Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro,” PLoS One, vol. 8, no. 5, article e64526, 2013. View at: Publisher Site | Google Scholar
  35. G. Chi, W. Zhong, Y. Liu et al., “Isorhamnetin protects mice from lipopolysaccharide-induced acute lung injury via the inhibition of inflammatory responses,” Inflammation Research, vol. 65, no. 1, pp. 33–41, 2016. View at: Publisher Site | Google Scholar
  36. S. Qiu, G. Sun, Y. Zhang, X. Li, and R. Wang, “Involvement of the NF-κB signaling pathway in the renoprotective effects of isorhamnetin in a type 2 diabetic rat model,” Biomedical Reports, vol. 4, no. 5, pp. 628–634, 2016. View at: Publisher Site | Google Scholar
  37. L. Gao, R. Yao, Y. Liu et al., “Isorhamnetin protects against cardiac hypertrophy through blocking PI3K-AKT pathway,” Molecular and Cellular Biochemistry, vol. 429, no. 1-2, pp. 167–177, 2017. View at: Publisher Site | Google Scholar
  38. L. Li, Z. Hu, W. Li et al., “Establishment of a standardized liver fibrosis model with different pathological stages in rats,” Gastroenterology Research and Practice, vol. 2012, Article ID 560345, 6 pages, 2012. View at: Publisher Site | Google Scholar
  39. C. G. Tag, S. Sauer-Lehnen, S. Weiskirchen et al., “Bile duct ligation in mice: induction of inflammatory liver injury and fibrosis by obstructive cholestasis,” Journal of Visualized Experiments, no. 96, article e52438, 2015. View at: Publisher Site | Google Scholar
  40. E. G. Giannini, R. Testa, and V. Savarino, “Liver enzyme alteration: a guide for clinicians,” CMAJ, vol. 172, no. 3, pp. 367–379, 2005. View at: Publisher Site | Google Scholar
  41. M. Li, K. Song, X. Huang, S. Fu, and Q. Zeng, “GDF-15 prevents LPS and D-galactosamine-induced inflammation and acute liver injury in mice,” International Journal of Molecular Medicine, vol. 42, no. 3, pp. 1756–1764, 2018. View at: Publisher Site | Google Scholar
  42. Q. Yu, T. Liu, S. Li et al., “The protective effects of Levo-tetrahydropalmatine on ConA-induced liver injury are via TRAF6/JNK signaling,” Mediators of Inflammation, vol. 2018, Article ID 4032484, 15 pages, 2018. View at: Publisher Site | Google Scholar
  43. C. Bonnans, J. Chou, and Z. Werb, “Remodelling the extracellular matrix in development and disease,” Nature Reviews Molecular Cell Biology, vol. 15, no. 12, pp. 786–801, 2014. View at: Publisher Site | Google Scholar
  44. S. Duarte, J. Baber, T. Fujii, and A. J. Coito, “Matrix metalloproteinases in liver injury, repair and fibrosis,” Matrix Biology, vol. 44-46, pp. 147–156, 2015. View at: Publisher Site | Google Scholar
  45. F. Zhang, D. Kong, Y. Lu, and S. Zheng, “Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside,” Cellular and Molecular Life Sciences, vol. 70, no. 2, pp. 259–276, 2013. View at: Publisher Site | Google Scholar
  46. Z. Wang, J. P. Xu, Y. C. Zheng et al., “Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats,” Hepatobiliary & Pancreatic Diseases International, vol. 10, no. 1, pp. 64–71, 2011. View at: Publisher Site | Google Scholar
  47. A. Pellicoro, P. Ramachandran, J. P. Iredale, and J. A. Fallowfield, “Liver fibrosis and repair: immune regulation of wound healing in a solid organ,” Nature Reviews Immunology, vol. 14, no. 3, pp. 181–194, 2014. View at: Publisher Site | Google Scholar
  48. E. Seki and R. F. Schwabe, “Hepatic inflammation and fibrosis: functional links and key pathways,” Hepatology, vol. 61, no. 3, pp. 1066–1079, 2015. View at: Publisher Site | Google Scholar
  49. N. Nieto, J. A. Dominguez-Rosales, L. Fontana et al., “Rat hepatic stellate cells contribute to the acute-phase response with increased expression of α1(I) and α1(IV) collagens, tissue inhibitor of metalloproteinase-1, and matrix-metalloproteinase-2 messenger RNAs,” Hepatology, vol. 33, no. 3, pp. 597–607, 2001. View at: Publisher Site | Google Scholar
  50. H. Herbst, T. Wege, S. Milani et al., “Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis,” The American Journal of Pathology, vol. 150, no. 5, pp. 1647–1659, 1997. View at: Google Scholar
  51. J. H. Choi, S. W. Jin, C. Y. Choi et al., “Capsaicin inhibits dimethylnitrosamine-induced hepatic fibrosis by inhibiting the TGF-β1/Smad pathway via peroxisome proliferator-activated receptor gamma activation,” Journal of Agricultural and Food Chemistry, vol. 65, no. 2, pp. 317–326, 2017. View at: Publisher Site | Google Scholar
  52. L. Caja, F. Dituri, S. Mancarella et al., “TGF-β and the tissue microenvironment: relevance in fibrosis and cancer,” International Journal of Molecular Sciences, vol. 19, no. 5, p. 1294, 2018. View at: Publisher Site | Google Scholar
  53. C. J. Parsons, M. Takashima, and R. A. Rippe, “Molecular mechanisms of hepatic fibrogenesis,” Journal of Gastroenterology and Hepatology, vol. 22, Supplement 1, pp. S79–S84, 2007. View at: Publisher Site | Google Scholar
  54. I. Fabregat, J. Moreno-Càceres, A. Sánchez et al., “TGF-β signalling and liver disease,” The FEBS Journal, vol. 283, no. 12, pp. 2219–2232, 2016. View at: Publisher Site | Google Scholar
  55. G. Latella, A. Vetuschi, R. Sferra et al., “Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice,” Liver International, vol. 29, no. 7, pp. 997–1009, 2009. View at: Publisher Site | Google Scholar
  56. A. Masszi and A. Kapus, “Smaddening complexity: the role of Smad3 in epithelial-myofibroblast transition,” Cells, Tissues, Organs, vol. 193, no. 1-2, pp. 41–52, 2011. View at: Publisher Site | Google Scholar
  57. Y. Mao, S. Zhang, F. Yu, H. Li, C. Guo, and X. Fan, “Ghrelin attenuates liver fibrosis through regulation of TGF-β1 expression and autophagy,” International Journal of Molecular Sciences, vol. 16, no. 9, pp. 21911–21930, 2015. View at: Publisher Site | Google Scholar
  58. J. Y. Kim, H. J. An, W. H. Kim et al., “Anti-fibrotic effects of synthetic oligodeoxynucleotide for TGF-β1 and Smad in an animal model of liver cirrhosis,” Molecular Therapy - Nucleic Acids, vol. 8, pp. 250–263, 2017. View at: Publisher Site | Google Scholar
  59. X. Li, X. Wang, C. Han et al., “Astragaloside IV suppresses collagen production of activated hepatic stellate cells via oxidative stress-mediated p38 MAPK pathway,” Free Radical Biology & Medicine, vol. 60, pp. 168–176, 2013. View at: Publisher Site | Google Scholar
  60. X. Wang, C. Niu, X. Zhang, and M. Dong, “Emodin suppresses activation of hepatic stellate cells through p38 mitogen-activated protein kinase and Smad signaling pathways in vitro,” Phytotherapy Research, vol. 32, no. 12, pp. 2436–2446, 2018. View at: Publisher Site | Google Scholar
  61. S. Tsukada, J. K. Westwick, K. Ikejima, N. Sato, and R. A. Rippe, “SMAD and p38 MAPK signaling pathways independently regulate α1(I) collagen gene expression in unstimulated and transforming growth factor-β-stimulated hepatic stellate cells,” The Journal of Biological Chemistry, vol. 280, no. 11, pp. 10055–10064, 2005. View at: Publisher Site | Google Scholar
  62. Y. Song, Y. Zhao, F. Wang, L. Tao, J. Xiao, and C. Yang, “Autophagy in hepatic fibrosis,” BioMed Research International, vol. 2014, Article ID 436242, 8 pages, 2014. View at: Publisher Site | Google Scholar
  63. V. Hernandez-Gea and S. L. Friedman, “Autophagy fuels tissue fibrogenesis,” Autophagy, vol. 8, no. 5, pp. 849-850, 2012. View at: Publisher Site | Google Scholar
  64. B. Wang, H. Yang, Y. Fan et al., “3-Methyladenine ameliorates liver fibrosis through autophagy regulated by the NF-κB signaling pathways on hepatic stellate cell,” Oncotarget, vol. 8, no. 64, pp. 107603–107611, 2017. View at: Publisher Site | Google Scholar
  65. M. Chen, J. Liu, L. Yang, and W. Ling, “AMP-activated protein kinase regulates lipid metabolism and the fibrotic phenotype of hepatic stellate cells through inhibition of autophagy,” FEBS Open Bio, vol. 7, no. 6, pp. 811–820, 2017. View at: Publisher Site | Google Scholar
  66. H. Tong, H. Yin, M. A. Hossain et al., “Starvation-induced autophagy promotes the invasion and migration of human bladder cancer cells via TGF-β1/Smad3-mediated epithelial-mesenchymal transition activation,” Journal of Cellular Biochemistry, vol. 120, no. 4, pp. 5118–5127, 2019. View at: Publisher Site | Google Scholar

Copyright © 2019 Ning Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

658 Views | 393 Downloads | 2 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.